Provided by Tiger Fintech (Singapore) Pte. Ltd.

Inhibikase Therapeutics, Inc.

2.25
+0.01000.45%
Volume:116.49K
Turnover:264.13K
Market Cap:167.27M
PE:-1.94
High:2.37
Open:2.25
Low:2.20
Close:2.24
Loading ...

BRIEF-Q32 Bio Inc - Mark Iwicki Resigns From Q32 Bio Board Effective Dec 31, 2025

Reuters
·
26 Apr

Q32 Bio Inc - Iwicki Resigns to Focus on CEO Role at Inhibikase Therapeutics

THOMSON REUTERS
·
26 Apr

Q32 Bio Inc - Mark Iwicki Resigns From Q32 Bio Board Effective Dec 31, 2025

THOMSON REUTERS
·
26 Apr

BRIEF-Inhibikase Therapeutics Announces Appointment Of David Mcintyre As CFO

Reuters
·
14 Apr

Inhibikase Names McIntyre Finance Chief as Lees-Rolfe Resigns

Dow Jones
·
14 Apr

Inhibikase Therapeutics announces appointment of McIntyre as CFO

TIPRANKS
·
14 Apr

Press Release: Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer

Dow Jones
·
14 Apr

Hedge funds owners may consider drastic measures as Inhibikase Therapeutics, Inc.'s (NASDAQ:IKT) recent US$29m drop adds to long-term losses

Simply Wall St.
·
04 Apr

Inhibikase Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
28 Mar

Inhibikase Therapeutics FY 2024 GAAP EPS $(1.16) Misses $(0.90) Estimate

Benzinga
·
28 Mar

Press Release: Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity

Dow Jones
·
28 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
27 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
24 Mar

Inhibikase Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview

Reuters
·
21 Mar

Inhibikase Therapeutics (IKT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Zacks
·
05 Mar

Inhibikase Announces Expansion of Senior Leadership Team

THOMSON REUTERS
·
24 Feb

Inhibikase Announces Expansion of Senior Leadership Team

GlobeNewswire
·
24 Feb

Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company’s Growth

THOMSON REUTERS
·
18 Feb

HC Wainwright Downgrades Inhibikase Therapeutics to Neutral From Buy

MT Newswires Live
·
12 Feb

Inhibikase Therapeutics, Inc. : H.c. Wainwright Cuts to Neutral From Buy

THOMSON REUTERS
·
12 Feb